CDK18

Cyclin-dependent kinase 18

6,908 patent compounds predicted against CDK18, 6,246 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1168934	0.53	2/20
SCHEMBL1167921	0.43	2/20
Quizartinib (SCHEMBL72923)	1.00	1/20
Pictilisib (SCHEMBL190812)	1.00	1/20
SCHEMBL1192176	1.00	1/20
SCHEMBL1192177	1.00	1/20
Quizartinib (SCHEMBL74121)	0.99	1/20
Quizartinib (SCHEMBL742377)	0.99	1/20
SCHEMBL190513	0.95	1/20
SCHEMBL73633	0.93	1/20
SCHEMBL72924	0.91	1/20
Hydrochloric Acid (SCHEMBL74122)	0.90	1/20
Hydrochloric Acid (SCHEMBL742748)	0.90	1/20
SCHEMBL769118	0.89	1/20
SCHEMBL769608	0.89	1/20
SCHEMBL769721	0.89	1/20
SCHEMBL73035	0.88	1/20
SCHEMBL73476	0.88	1/20
SCHEMBL31205	0.88	1/20
SCHEMBL769326	0.88	1/20

Germline variants in CDK18 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK18 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK18 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	PHASE3	RECRUITING
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)	PHASE3	COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	PHASE1/PHASE2	UNKNOWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	PHASE2	COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations	PHASE2	COMPLETED
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy	PHASE2	UNKNOWN
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	WITHDRAWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy	nan	COMPLETED
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDK18 binder may also engage these)

Protein	Name	Similarity
Q5RD01	—	1.000	Q5RD01 →
O35832	—	1.000	O35832 →
Q04899	—	0.999	Q04899 →
C0RW22	—	0.995	C0RW22 →
O35831	—	0.994	O35831 →
B0VXL7	—	0.994	B0VXL7 →
Q8K0D0	—	0.993	Q8K0D0 →
CDK16	Cyclin-dependent kinase 16	0.992	landscape →
Q63686	—	0.992	Q63686 →
Q1RLU9	—	0.992	Q1RLU9 →
CDK14	Cyclin-dependent kinase 14	0.991	landscape →
B0VXE8	—	0.991	B0VXE8 →
Q6DJM7	—	0.991	Q6DJM7 →
A4IIW7	—	0.991	A4IIW7 →
O35495	—	0.991	O35495 →
CDK17	Cyclin-dependent kinase 17	0.990	landscape →
P43294	—	0.990	P43294 →
Q4WYR6	—	0.989	Q4WYR6 →
Q8VZD5	—	0.989	Q8VZD5 →
Q9C9U2	—	0.989	Q9C9U2 →
Q04735	—	0.989	Q04735 →
P51138	—	0.989	P51138 →
B6A7Q3	—	0.989	B6A7Q3 →
Q5BAE1	—	0.989	Q5BAE1 →
Q84SN3	—	0.988	Q84SN3 →
Q5VP69	—	0.987	Q5VP69 →
Q4FCZ5	—	0.987	Q4FCZ5 →
CDK15	Cyclin-dependent kinase 15	0.987	landscape →
P43289	—	0.987	P43289 →
O19111	—	0.987	O19111 →